Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations

Silvia Casagrande,Giulia Boscato Sopetto,Giovanni Bertalot,Roberto Bortolotti,Vito Racanelli,Orazio Caffo,Bruno Giometto,Alvise Berti,Antonello Veccia

DOI: https://doi.org/10.3390/cancers16071440

2024-04-09

Cancers

Abstract:The landscape of cancer treatment has undergone a significant transformation with the introduction of Immune Checkpoint Inhibitors (ICIs). Patients undergoing these treatments often report prolonged clinical and radiological responses, albeit with a potential risk of developing immune-related adverse events (irAEs). Here, we reviewed and discussed the mechanisms of action of ICIs and their pivotal role in regulating the immune system to enhance the anti-tumor immune response. We scrutinized the intricate pathogenic mechanisms responsible for irAEs, arising from the evasion of self-tolerance checkpoints due to drug-induced immune modulation. We also summarized the main clinical manifestations due to irAEs categorized by organ types, detailing their incidence and associated risk factors. The occurrence of irAEs is more frequent when ICIs are combined; with neurological, cardiovascular, hematological, and rheumatic irAEs more commonly linked to PD1/PD-L1 inhibitors and cutaneous and gastrointestinal irAEs more prevalent with CTLA4 inhibitors. Due to the often-nonspecific signs and symptoms, the diagnosis of irAEs (especially for those rare ones) can be challenging. The differential with primary autoimmune disorders becomes sometimes intricate, given the clinical and pathophysiological similarities. In conclusion, considering the escalating use of ICIs, this area of research necessitates additional clinical studies and practical insights, especially the development of biomarkers for predicting immune toxicities. In addition, there is a need for heightened education for both clinicians and patients to enhance understanding and awareness.

oncology

What problem does this paper attempt to address?

### Problems Addressed by the Paper

The paper primarily explores the immune mechanisms and clinical manifestations of immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). Specifically:

1. **Immune Mechanisms**: The paper discusses in detail the mechanisms by which ICIs enhance anti-tumor immune responses by blocking immune checkpoints (such as the CTLA-4 and PD-1/PD-L1 axis). These drugs improve the immune system's ability to recognize and attack tumor cells but may also lead to a loss of self-tolerance, thereby triggering irAEs.

2. **Clinical Manifestations**: The paper summarizes the main clinical manifestations of irAEs in different organs, including the skin, gastrointestinal tract, endocrine system, and lungs, and describes their incidence and risk factors in detail. For example:
- Skin manifestations (e.g., rash)
- Gastrointestinal manifestations (e.g., diarrhea, colitis, and hepatitis)
- Endocrine system manifestations (e.g., thyroiditis, hypothyroidism, and hyperthyroidism)
- Lung manifestations (e.g., pneumonia and interstitial lung disease)

3. **Impact of Different ICIs**: The paper also explores the specific differences in irAEs caused by different types of ICIs (such as CTLA-4 inhibitors and PD-1/PD-L1 inhibitors). For example:
- PD-1/PD-L1 inhibitors are more likely to cause irAEs in the nervous system, cardiovascular system, hematologic system, and rheumatic system.
- CTLA-4 inhibitors are more likely to cause irAEs in the skin and gastrointestinal tract.

4. **Comparison with Autoimmune Diseases**: Since irAEs share similarities in pathophysiology and clinical manifestations with certain primary autoimmune diseases, the paper emphasizes the importance of distinguishing irAEs from these autoimmune diseases.

5. **Future Research Directions**: The paper points out that with the increasing use of ICIs, further research is needed to develop biomarkers for predicting immune toxicity and to enhance education for doctors and patients to improve the recognition and management of irAEs.

In summary, this review aims to comprehensively summarize the mechanisms and clinical manifestations of irAEs caused by ICIs and highlights the need for research in this field.